Stay up-to-date on current diabetes themes, proven therapeutic options, and knowledge resources and tools for you and your patients, and find detailed information on Novo Nordisk diabetes products.
Since the launch of its first pen needle in 1985, Novo Nordisk has been committed to enhancing injection experience
by putting technology in patient hands. NovoFine® Plus is the latest example of that commitment.
We have products for rare bleeding disorders, growth hormone-related disorders, and women’s health.
Chronic Weight Management
Find information on our treatment for chronic weight management in adults who are overweight with one weight-related comorbidity or obesity.
We are world leaders in diabetes care with a growing business in other treatment areas like haemophilia. We are more than 39,000 employees in 75 countries. Join us!
(insulin degludec injection)
Click here for Tresiba® Prescribing Information
(liraglutide [rDNA origin] injection)
Click here for Victoza® Prescribing Information
(insulin detemir [rDNA origin] injection)
Click here for Levemir® Prescribing Information
(insulin aspart [rDNA origin] injection)
Click here for NovoLog® Prescribing Information
NovoLog® Mix 70/30
(70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin])
Click here for NovoLog® Mix 70/30 Prescribing Information
Click here for Prandin® Prescribing Information
(glucagon [rDNA origin] for injection)
More information about GlucaGen® HypoKit®
Click here for GlucaGen® HypoKit® Prescribing Information
© 2016 Novo Nordisk All rights reserved. USA15DEP01789 February 2016